Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Apr 8;33(4):190–198. doi: 10.1002/clc.20681

Should We Measure C‐reactive Protein on Earth or Just on JUPITER?

Ambareesh Bajpai 1, Abhinav Goyal 1, Laurence Sperling 1,✉
PMCID: PMC6653384  PMID: 20394038

Abstract

Evidence for the role of inflammation in the pathogenesis of atherosclerosis is compelling and has generated interest in high‐sensitivity C‐reactive protein (hs‐CRP) as a marker of cardiovascular risk. Data regarding hs‐CRP and cardiovascular risk, though largely consistent, is of unclear clinical relevance. Most recently, the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial has led to further debate regarding the utility of hs‐CRP. This article provides a comprehensive review of the data regarding cardiovascular risk and hs‐CRP with an emphasis on the JUPITER trial and concludes with an evidence‐based analysis of the current role of hs‐CRP in cardiovascular risk assessment. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (174.8 KB).

References

  • 1. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med 2008; 359(21): 2195–2207. [DOI] [PubMed] [Google Scholar]
  • 2. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104(15): 1863–1867. [DOI] [PubMed] [Google Scholar]
  • 3. Kushner I. C‐reactive protein and the acute‐phase response. Hosp Pract (Off Ed) 1990; 25(3A): 13,16,21–8. [PubMed] [Google Scholar]
  • 4. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C‐reactive protein in health and disease. J Clin Invest 1993; 91(4): 1351–1357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Chang MK, Binder CJ, Torzewski M, et al. C‐reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99(20): 13043–13048. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Vigo C. Effect of C‐reactive protein on platelet‐activating factor‐induced platelet aggregation and membrane stabilization. J Biol Chem 1985; 260(6): 3418–3422. [PubMed] [Google Scholar]
  • 7. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for C‐reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109(15): 1870–1876. [DOI] [PubMed] [Google Scholar]
  • 8. Volanakis JE, Narkates AJ. Binding of human C4 to C‐reactive protein‐pneumococcal C‐polysaccharide complexes during activation of the classical complement pathway. Mol Immunol 1983; 20(11): 1201–1207. [DOI] [PubMed] [Google Scholar]
  • 9. Casas JP, Shah T, Hingorani AD, et al. C‐reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264(4): 295–314. [DOI] [PubMed] [Google Scholar]
  • 10. Zacho J, Tybjaerg‐Hansen A, Jensen JS, et al. Genetically elevated C‐reactive protein and ischemic vascular disease. N Engl J Med 2008; 359(18): 1897–1908. [DOI] [PubMed] [Google Scholar]
  • 11. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for human C‐reactive protein. Clin Chim Acta 1981; 117(1): 13–23. [DOI] [PubMed] [Google Scholar]
  • 12. Woloshin S, Schwartz LM. Distribution of C‐reactive protein values in the United States. N Engl J Med 2005; 352(15): 1611–1613. [DOI] [PubMed] [Google Scholar]
  • 13. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005; 165(2): 221–226. [DOI] [PubMed] [Google Scholar]
  • 14. Danesh J, Wheeler JG, Hirschfield GM, et al. C‐reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350(14): 1387–1397. [DOI] [PubMed] [Google Scholar]
  • 15. Ridker PM, Rifai N, Pfeffer MA, et al. The Cholesterol and Recurrent Events (CARE) Investigators. Long‐term effects of pravastatin on plasma concentration of C‐reactive protein. Circulation 1999; 100(3): 230–235. [DOI] [PubMed] [Google Scholar]
  • 16. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C‐reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344(26): 1959–1965. [DOI] [PubMed] [Google Scholar]
  • 17. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336(14): 973–979. [DOI] [PubMed] [Google Scholar]
  • 18. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta‐analyses. BMJ 2000; 321(7255): 199–204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Sakkinen P, Abbott RD, Curb JD, et al. C‐reactive protein and myocardial infarction. J Clin Epidemiol 2002; 55(5): 445–451. [DOI] [PubMed] [Google Scholar]
  • 20. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288(8): 980–987. [DOI] [PubMed] [Google Scholar]
  • 21. Ridker PM, Rifai N, Rose L, et al. Comparison of C‐reactive protein and low‐density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347(20): 1557–1565. [DOI] [PubMed] [Google Scholar]
  • 22. Luc G, Bard JM, Juhan‐Vague I, et al. C‐reactive protein, interleukin‐6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23(7): 1255–1261. [DOI] [PubMed] [Google Scholar]
  • 23. Tice JA, Browner W, Tracy RP, et al. The relation of C‐reactive protein levels to total and cardiovascular mortality in older U.S. women. Am J Med 2003; 114(3): 199–205. [DOI] [PubMed] [Google Scholar]
  • 24. Ballantyne CM, Hoogevecn RC, Bang H, et al. Lipoprotein‐associated phospholipase A2, high‐sensitivity C‐reactive protein, and risk for incident coronary heart disease in middle‐aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109(7): 837–842. [DOI] [PubMed] [Google Scholar]
  • 25. Lowe GD, Sweetnam PM, Yarnell JW, et al. C‐reactive protein, fibrin D‐dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies. Arterioscler Thromb Vasc Biol 2004; 24(10): 1957–1962. [DOI] [PubMed] [Google Scholar]
  • 26. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351(25): 2599–2610. [DOI] [PubMed] [Google Scholar]
  • 27. Lowe GD, Rumley A, McMahon AD, et al. Interleukin‐6, fibrin D‐dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24(8): 1529–1534. [DOI] [PubMed] [Google Scholar]
  • 28. Cushman M, Arnold AM, Psaty BM, et al. C‐reactive protein and the 10‐year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 2005; 112(1): 25–31. [DOI] [PubMed] [Google Scholar]
  • 29. Laaksonen DE, Niskanen L, Nyyssonen K, et al. C‐reactive protein in the prediction of cardiovascular and overall mortality in middle‐aged men: a population‐based cohort study. Eur Heart J 2005; 26(17): 1783–1789. [DOI] [PubMed] [Google Scholar]
  • 30. Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C‐reactive protein and IL‐6 but not IL‐18 are independently associated with incident coronary events in middle‐aged men and women: results from the MONICA/KORA Augsburg case‐cohort study, 1984–2002. Arterioscler Thromb Vasc Biol 2006; 26(12): 2745–2751. [DOI] [PubMed] [Google Scholar]
  • 31. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C‐reactive protein, and 5‐year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19(12): 3071–3078. [DOI] [PubMed] [Google Scholar]
  • 32. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin‐6 and C‐reactive protein levels with mortality in the elderly. Am J Med 1999; 106(5): 506–512. [DOI] [PubMed] [Google Scholar]
  • 33. Pirro M, Bergeron J, Dagenais GR, et al. Age and duration of follow‐up as modulators of the risk for ischemic heart disease associated with high plasma C‐reactive protein levels in men. Arch Intern Med 2001; 161(20): 2474–2480. [DOI] [PubMed] [Google Scholar]
  • 34. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108(19): 2317–2322. [DOI] [PubMed] [Google Scholar]
  • 35. van der Meer IM, de Maat MP, Kiliaan AJ, et al. The value of C‐reactive protein in cardiovascular risk prediction: the Rotterdam Study. Arch Intern Med 2003; 163(11): 1323–1328. [DOI] [PubMed] [Google Scholar]
  • 36. Wilson PW, Nam BH, Pencina M, et al. C‐reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch Intern Med 2005; 165(21): 2473–2478. [DOI] [PubMed] [Google Scholar]
  • 37. Cook NR, Buring JE, Ridker PM. The effect of including C‐reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006; 145(1): 21–29. [DOI] [PubMed] [Google Scholar]
  • 38. Ridker PM, Rifai N, Cook NR, et al. Non‐HDL cholesterol, apolipoproteins A‐I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294(3): 326–333. [DOI] [PubMed] [Google Scholar]
  • 39. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C‐reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286(1): 64–70. [DOI] [PubMed] [Google Scholar]
  • 40. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290(7): 898–904. [DOI] [PubMed] [Google Scholar]
  • 41. Ridker PM, Morrow DA, Rose LM, et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low‐density lipoprotein cholesterol < 70 mg/dL and C‐reactive protein < 2 mg/L: an analysis of the PROVE‐IT TIMI‐22 trial. J Am Coll Cardiol 2005; 45(10): 1644–1648. [DOI] [PubMed] [Google Scholar]
  • 42. Ridker PM, Glynn R. Rosuvastatin for the prevention of stroke among men and women with elevated levels of C‐reactive protein: The JUPITER trial. International Stroke Conference, 2009; (Abstract 140).
  • 43. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C‐reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373(9670): 1175–1182. [DOI] [PubMed] [Google Scholar]
  • 44. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009: 360(18): 1851–1861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Titcolor Disease Control and Prevention and the American Heart Association. Circulation 2003; 107(3): 499–511. [DOI] [PubMed] [Google Scholar]
  • 46. Titcolor Spatz ESTitcolor, Titcolor Canavan CMTitcolor, Titcolor Desai MM. TitcolorFrom here to JUPITER. Circulation Cardiovascular Quality and Outcomes, 2009. [DOI] [PubMed]
  • 47. Ridker PM, Paynter NP, Rifai N, et al. C‐reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008; 118(22): 2243–2251, 4p following 2251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297(6): 611–619. [DOI] [PubMed] [Google Scholar]
  • 49. Hlatky MA, Greenland P, Amett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119(17): 2408–2416. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES